期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
山东省济宁市病毒性腹泻样本诺如病毒分子流行病学与基因特征分析 被引量:2
1
作者 颜丙新 姜文国 +1 位作者 傅忠燕 靳淼 《预防医学论坛》 2023年第2期96-98,共3页
目的了解山东省济宁市诺如病毒的分子流行病学特征及诺如病毒的优势基因型,为诺如病毒感染防控提供科学依据。方法按照《山东省病毒性腹泻监测方案》,2018年1月-2020年12月从山东省济宁市每县(市、区)每月采集3~5份病毒性腹泻标本,进行... 目的了解山东省济宁市诺如病毒的分子流行病学特征及诺如病毒的优势基因型,为诺如病毒感染防控提供科学依据。方法按照《山东省病毒性腹泻监测方案》,2018年1月-2020年12月从山东省济宁市每县(市、区)每月采集3~5份病毒性腹泻标本,进行流行病学调查,采用Real time RT-PCR方法检测诺如病毒GI/GⅡ组,对阳性样本进行基因型别鉴定。结果共采集粪便标本1230份,诺如病毒阳性165份(其中GⅠ8份、GⅡ157份),检出率为13.41%(165/1230)。每年除2月份外,其他月份均检出诺如病毒,以6月、7月检出率高。基因型分别为GⅡ.4型25份,占32.05%;GⅡ.2型18份,占23.08%;GⅡ.6型14份,占17.95%;GⅡ.3型13份,占16.67%。3年间优势毒株不同,2018年为GⅡ.3型9份,占69.23%;2019年为GⅡ.2型14份,占43.75%;2020年为GⅡ.4型17份,占53.13%。结论山东省济宁市诺如病毒感染6月和7月流行强度较强,以GⅡ组为主,基因型存在多样性,处于动态变化中,以GⅡ.2[P16]型和GⅡ.4[P31]型为主要型别。 展开更多
关键词 诺如病毒 病毒性腹泻 急性肠胃炎 基因型 分子流行病学
原文传递
诺如病毒GIX.1[GII.P15]型山东株SD20191568全基因组序列特征分析 被引量:3
2
作者 傅忠燕 刘莉 +6 位作者 孔翔羽 韩扬 徐爱强 靳淼 庞立丽 章青 段招军 《中国病原生物学杂志》 CSCD 北大核心 2020年第12期1365-1369,共5页
目的分析诺如病毒山东株SD20191568全基因组序列,了解其基因组结构特点。方法取诺如病毒阳性者粪便,提取核酸。根据诺如病毒参考株序列设计引物,用RT-PCR分段扩增病毒全基因组,经测序后进行核苷酸、氨基酸序列比对和系统进化分析。结果... 目的分析诺如病毒山东株SD20191568全基因组序列,了解其基因组结构特点。方法取诺如病毒阳性者粪便,提取核酸。根据诺如病毒参考株序列设计引物,用RT-PCR分段扩增病毒全基因组,经测序后进行核苷酸、氨基酸序列比对和系统进化分析。结果通过扩增获得SD20191568株接近完整的基因组序列,由7470个核苷酸(nt)组成,在ORF1和ORF2分别属于GII.P15和GIX.1基因型,SD20191568株在ORF1、ORF2和ORF3与GIX.1[GII.P15]基因型参考株的核苷酸同源性分别是90.1%~98.8%、92.7%~98.8%和92.2%~97.3%。根据完整VP1核苷酸系统进化分析,来自GenBank的GIX.1型参考株分为6个基因群(ClusterA-F),SD20191568株与2016-2018年的毒株共同划分在F群,核苷酸同源性为97.2%~98.8%。通过衣壳区氨基酸比对,SD20191568株与F群参考株氨基酸序列相同,未发生变异。结论诺如病毒山东株SD20191568属于GIX.1[GII.P15]型毒株,VP1区核苷酸与原型株差异较大,全长序列可为病毒的遗传进化研究、快速诊断试剂的研制及疫苗的设计提供参考。 展开更多
关键词 诺如病毒 GIX.1基因型 全基因组 序列分析
原文传递
Effects of emodin on gene expression profile in small cell lung cancer NCI-H446 cells 被引量:15
3
作者 fu zhong-yan HAN Jin-xiang HUANG Hai-yan 《Chinese Medical Journal》 SCIE CAS CSCD 2007年第19期1710-1715,共6页
Background The treatment of patients with small cell lung cancer (SCLC) is based on chemotherapy. However, the treatment is limited by the development of drug resistance. Emodin has been shown to exhibit an anti-can... Background The treatment of patients with small cell lung cancer (SCLC) is based on chemotherapy. However, the treatment is limited by the development of drug resistance. Emodin has been shown to exhibit an anti-cancer effect. But the molecular mechanism remains unclear. This study was conducted to investigate the effect of emodin on the gene expression profile changes in SCLC NCI-H446 cells. Methods NCI-H446 cells were treated with emodin and cell viability was determined by MTT assay. Cell apoptosis was determined by both flow cytometry and caspase-3 activity assay. The effect of emodin on the gene expression profile of NCI-H446 cells was analyzed using cDNA microarray. Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used to validate the microarray results. Results Emodin suppressed viability, induced apoptosis and changed cell cycle of NCI-H446 cells. Among the 1262 genes, 10 genes were up-regulated and 8 genes were down-regulated more than 2 folds in NCI-H446 cells when compared with the control cells after treatment with emodin for 12 hours, while 12 genes were up-regulated and 24 genes were down-regulated after treatment with emodin for 24 hours. These genes were involved in metabolism, signal transduction, transcription regulation, cytoskeleton organization, immune response, transport, protein synthesis, cell cycle control, cell adhesion and RNA processing. The RT-PCR results were consistent with those obtained by the microarray. Conclusions Emodin affects the expression of genes involved in various cellular functions and plays important roles in cell apoptosis, tumor metastasis and chemotherapy-resistance, which suggests emodin might become an effective chemopreventive or chemotherapeutic agent for SCLC. 展开更多
关键词 EMODIN small cell lung cancer gene expression profile
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部